Volume 7.16 | Apr 30

Cord Blood News 7.16 April 30, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
Phenotypic and Immunomodulatory Properties of Equine Cord Blood-Derived Mesenchymal Stromal Cells
Scientists hypothesized that mesenchymal stromal cells can be consistently isolated from equine cord blood, have unique and reproducible marker expression, and in vitro suppress lymphoproliferation. [PLoS One] Full Article
View Data: StemSpan™ SFEM II Serum-Free Medium
PUBLICATIONS (Ranked by impact factor of the journal)
Human Adipose-Tissue Derived Stromal Cells in Combination with Hypoxia Effectively Support Ex Vivo Expansion of Cord Blood Hematopoietic Progenitors
Hematopoietic stem/progenitor cells (HSPCs) were selected from unmanipulated cord blood mononuclear cells due to adhesion to human adipose-tissue derived stromal cells (ASCs) under standard and tissue-related oxygen. ASCs efficiently maintained viability and supported further HSPC expansion at 20% and 5% O2. [PLoS One] Full Article

Comparative Study between Amniotic-Fluid Mesenchymal Stem Cells and Retinal Pigmented Epithelium (RPE) Stem Cells Ability to Differentiate towards RPE Cells
Amniotic fluid-derived mesenchymal stem cells and RPE stem cells were isolated, characterized to assay their stemness and induced to neuronal/retinal differentiation; specific RPE markers were then analyzed. [Cell Tissue Res] Abstract

Stem Cell Factor Is Essential for Preserving NOD/SCID Reconstitution Capacity of Ex Vivo Expanded Cord Blood CD34+ Cells
CD34+ cells were cultured with or without stem cell factor supplementation in serum-free medium for ten days. Expanded cells were transplanted into sublethally irradiated non-obese diabetic/severe combined immune-deficient (NOD/SCID) mice. Engraftment and multilineage reconstitution of transplanted cells were determined. [Cell Prolif] Abstract

UV-Activated 7-Dehydrocholesterol-Coated Titanium Implants Promote Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Osteoblasts
Investigators examined the impact of titanium implants surfaces coated with UV-irradiated 7-dehydrocholesterol on the osteogenic differentiation of human umbilical cord mesenchymal stem cells. [J Biomater Appl] Abstract

Induction of Insulin-Producing Cells from Umbilical Cord Blood-Derived Stromal Cells by Activation of the c-Met/HGF Axis
Researchers attempted to differentiate adult stem cells produced from umbilical cord blood-derived stromal cells into insulin-producing cells (IPCs). By activating the c-Met/HGF axis through temporal hypoxia treatment and hepatocyte growth factor supplementation, their protocol resulted in the differentiation of cells into functional pancreatic endocrine cells with increased viability. [Dev Growth Differ] Abstract

Human Mesenchymal Stem Cells Improve the Neurodegeneration of Femoral Nerve in a Diabetic Foot Ulceration Rats
Scientists explored the potential role of human mesenchymal stem cells-umbilical cord blood (hMSCs-UC) in femoral nerve neuropathy. In hMSCs-UC-treated model rats, serum NGF was increased with higher positive rate of NF-200. [Neurosci Lett] Abstract

The Role of Children’s Bone Marrow Mesenchymal Stromal Cells in the Ex Vivo Expansion of Autologous and Allogeneic Hematopoietic Stem Cells
Researchers evaluated the effects of children’s bone marrow mesenchymal stromal cells on the ex vivo expansion capacity of both allogeneic cord blood and autologous bone marrow CD34+ hematopoietic stem cells when used as a cell feeder layer with or without recombinant cytokines. [Cell Biol Int] Abstract

Similar Outcomes of Allogeneic Hematopoietic Cell Transplantation from Unrelated Donor and Umbilical Cord Blood vs. Sibling Donor for Pediatric Acute Myeloid Leukemia: Multicenter Experience in China
Investigators conducted a retrospective study on 73 pediatric acute myeloid leukemia patients who were primary refractory or in greater than CR1 and investigated MSD, URD, and UCB hematopoietic cell transplantation. [Pediatr Transplant] Abstract

Register Now for Live Webinar: New Tools for the Ex Vivo Expansion of Human Hematopoietic Stem and Progenitor Cells
Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis
Technical and safety concerns still limit the possibility of clinical applications of other promising interventions that are based on the use of human amnion stem cells, embryonic stem cells or induced pluripotent stem cells to replace or regenerate the dysfunctional alveolar epithelium. The authors summarize the current status of the field and identify major challenges and opportunities for the possible future integration of stem cell-based treatments into the currently recommended clinical management strategy for idiopathic pulmonary fibrosis. [Stem Cell Rev] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Targazyme, Inc., Announces FDA Concurrence on Targazyme’s Special Protocol Assessment for a Planned Phase III Registration Trial for the Treatment of Patients with Hematologic Malignancies
Targazyme, Inc. announced that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company’s Special Protocol Assessment application for its Phase III registration trial. This pivotal trial is designed to evaluate the efficacy of TZ101-treated cells in patients with hematologic malignancies undergoing hematopoietic stem cell (cord blood) transplantation with the primary outcome measure being time to neutrophil engraftment. [Targazyme, Inc.] Press Release

Genmab Announces Phase III Study of Arzerra® Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival in patients with relapsed chronic lymphocytic leukemia (CLL) compared to those given fludarabine and cyclophosphamide alone. [Genmab A/S] Press Release

From our sponsor:
Modify hPSC genomes and enhance the physiological relevance of your research?
Watch the webinar now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cells: From Robert Hooke to Cell Therapy – A 350 Year Journey
October 5-6, 2015
London, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Researcher – Hematopoietic Stem Cell Physiology and Pathophysiology (International Research Center for Medical Sciences)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford-Burnham Medical Research Institute)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (University of Leuven)

Postdoctoral Fellow – Hematopoietic Stem Cell Research (Lund University)

Postdoctoral Research Fellow – Stem Cell/Hematopoiesis Research (BloodCenter of Wisconsin)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University School of Medicine)

Postdoctoral Fellows – Leukemia Research and Stem Cell Biology (Josep Carreras Leukemia Research Institute)

Cord Tissue Processing Technician (Cord Blood Registry)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us